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Abstract
Background: Up to 90 % of people living with dementia in care homes experience one or more behaviours that
staff may describe as challenging to support (BSC). Of these agitation is the most common and difficult to manage.
The presence of agitation is associated with fewer visits from relatives, poorer quality of life and social isolation. It is
recommended that agitation is treated through psychosocial interventions. Dementia Care Mapping™ (DCM™) is an
established, widely used observational tool and practice development cycle, for ensuring a systematic approach to
providing person-centred care. There is a body of practice-based literature and experience to suggests that
DCM™ is potentially effective but limited robust evidence for its effectiveness, and no examination of its cost-effectiveness,
as a UK health care intervention. Therefore, a definitive randomised controlled trial (RCT) of DCM™ in the UK is urgently
needed.
Methods/design: A pragmatic, multi-centre, cluster-randomised controlled trial of Dementia Care Mapping (DCM™) plus
Usual Care (UC) versus UC alone, where UC is the normal care delivered within the care home following a minimum level
of dementia awareness training. The trial will take place in residential, nursing and dementia-specialist care homes across
West Yorkshire, Oxfordshire and London, with residents with dementia. A random sample of 50 care homes
will be selected within which a minimum of 750 residents will be registered. Care homes will be randomised
in an allocation ratio of 3:2 to receive either intervention or control. Outcome measures will be obtained at 6
and 16 months following randomisation. The primary outcome is agitation as measured by the Cohen-Mansfield
Agitation Inventory, at 16 months post randomisation. Key secondary outcomes are other BSC and quality of life. There
will be an integral cost-effectiveness analysis and a process evaluation.
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Discussion: The protocol was refined following a pilot of trial procedures. Changes include replacement of a
questionnaire, whose wording caused some residents distress, to an adapted version specifically designed for
use in care homes, a change to the randomisation stratification factors, adaption in how the staff measures
are collected to encourage greater compliance, and additional reminders to intervention homes of when
mapping cycles are due, via text message.
Trial registration: Current Controlled Trials ISRCTN82288852. Registered on 16 January 2014.
Full protocol version and date: v7.1: 18 December 2015.
Keywords: Agitation, Care homes, Cluster-randomised controlled trial, Dementia, Dementia Care Mapping,
Person-centred care
Background
A third of people who have dementia reside in a care
home [1] and at least two thirds of people living in care
homes have dementia [2]. Of the people living with
dementia, up to 90 % experience one or more behav-
iours that staff may describe as ‘challenging’ to support
(BSC), during the course of their condition. BSC include
behaviours such as agitation, aggression, restlessness,
hallucinations, delusions, depression, anxiety and apathy
[3]. The most common of these, with reported preva-
lence rates of over 60 % in nursing home residents with
dementia, is agitation [4, 5], which includes a cluster of
extremely problematic behaviours such as aggressive and
physically non-aggressive behaviours and verbal agitation
[6]. The presence of agitation in a person with dementia
is associated with fewer visits from relatives, poorer
quality of life [7] and social isolation [8]. Furthermore, it
puts the person who is agitated at risk of triggering
responses from other residents [9], causing potential
serious risk of harm not only to the person who is
agitated, but to other residents and staff. Agitation
and other BSC are not an inevitable consequence of
dementia, they reflect an expression of unmet needs
by a person with dementia in response to poor qual-
ity care [10–12]. It is recognised that the presence of
agitation in individuals with dementia in care home
settings is associated with poorer levels of organi-
sational aspects of care and the care culture [11]. It
is, therefore, recommended that agitation is treated
through the use of psychosocial interventions that
address the quality of care practice [10, 13].
Person-centred care is an effective psychosocial
approach in dementia care [14] and is considered a best
practice method for reducing agitation and other BSC
[13]. Person-centred care means providing a supportive
social environment within a care setting where people
with dementia are valued, treated as individuals, and
staff are encouraged to see the world from the person’s
perspective [13, 15]. Raising staff knowledge, skills and
confidence levels around person-centred ways of working
with BSC is, therefore, a national priority area [16–18].
Training staff in person-centred approaches has been
found to be effective in improving the delivery of person-
centred care [19, 20]. However, whilst effective person-
centred care training can produce immediate practice
benefits, evidence suggests that alone it might not sustain
change over time [19–22] and additional support is
required in order to facilitate sustained benefits [23] over
an extended period of time [24].
Dementia Care Mapping™ (DCM™) [25, 26] is an esta-
blished and widely used intervention, directed at care
homes, for ensuring a systematic approach to providing
individualised person-centred care, and is recommended
by the National Institute for Clinical Excellence/Social
Care Institute for Excellence (NICE/SCIE) [13]. DCM™
is an observational tool, set within a practice develop-
ment cycle, which includes five phases: (1) briefing, (2)
observation, (3) analysis, (4) feedback, and (5) action
planning. This cycle is repeated every 4–6 months to
monitor and revise action plans. Once initial training
and skills development in the method are completed,
those trained to use DCM™ (mappers) are able to conduct
these practice development cycles (mapping) indepen-
dently. This means that DCM™ requires no external input
over the long term and is, therefore, potentially less
resource intensive and more likely to be readily imple-
mented in real-world dementia practice than other inter-
ventions [27]. Whilst DCM™ has been used in
dementia care for nearly 20 years, including imple-
mentation in care home settings [28–32], and has
strong face validity within the practice field [33],
there is limited robust evidence of its efficacy in rela-
tion to clinical outcomes such as reduction of BSC.
Practice implementation suggests that the benefits of
DCM™ include the improvement of well-being in
service users [34–36] and helping staff see care from
the point of view of the person with dementia, lea-
ding to evidence-based feedback and action planning
that motivates staff and helps them to feel more
confident to implement person-centred care [32, 33].
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To date there are only five published studies that
examine the benefits of using DCM™ for improving
clinical outcomes. A Dutch pilot study [37] utilising a
One-Group Pretest-Posttest design found DCM™, used
alone, reduced verbal agitation and anxiety in people
with dementia and improved care staff feelings of
connection with clients. An Australian pilot study
[38] in three care homes, employing a Pretest-Posttest
design, found improvements in the quality of staff
interactions and reductions in agitation and depres-
sion through the use of DCM™. There are three full
RCTs of the effectiveness of DCM™ published to date.
A cluster RCT conducted in 15 care homes with 289
residents (loss to follow-up of 18 % at 10 months) in
Australia [14] (UC = 5, UC + person-centred care
training = 5, UC + DCM= 5), found that at 10 months
post randomisation, DCM™, when used alone was
associated with significantly reduced agitation and
falls among residents with dementia compared to UC.
A Norwegian cluster RCT [39] in 15 care homes (5 =
control group, 5 = person-centred care framework
implementation, 5 = DCM) and with 446 residents
(loss to follow-up of 29 % at 10 months) found a
significant reduction in neuropsychiatric symptoms as
measured by the Neuropsychiatric Inventory (NPI)
and on the NPI sub-scales of agitation and psychosis
compared to controls. It also found a significant
improvement in quality of life, compared to controls after
10-month follow-up. However, both the Norwegian and
the Australian study had a follow-up period of only 10
months, limiting the potential for impact given the length
of time that changes within practice can take to imple-
ment and thus potential benefits to be observed. Add-
itionally, both trials had explanatory designs involving
researcher-led cycles of DCM™ with variable degrees
of input from trained care home staff. This restricts
generalisability of the results to usual implementation
of DCM™ in care practice, which is practitioner-led. A
cluster RCT study in 34 units, from 11 care homes in
the Netherlands [40], with 434 residents (loss to
follow-up 35 % at 12 months) found no difference in
residents’ agitation between the DCM™ intervention
and control homes. However, staff in the intervention
group reported significantly fewer negative emotional
reactions and significantly more positive reactions
towards people with dementia over time. This trial
reported potential intervention fidelity issues in the
DCM™ care homes, indicating less than desirable im-
plementation of the intervention in some of the
clusters. A limitation of all three RCT studies is that
they were exploratory studies and each only included
two full cycles of DCM™ before final follow-up, redu-
cing the time for potential change and impact to be
realised.
Despite their limitations, these studies provide promi-
sing data on the effectiveness of DCM™ in Australian,
Norwegian and Dutch care home settings. They do not
provide, however, a robust evaluation of effectiveness of
DCM™ in UK settings. In particular, the Australian study
used DCM™ alone rather than alongside person-centred
care training, which is recommended in DCM imple-
mentation guidelines [41]. This reflects the Australian
context at the time of the study, where staff access to
person-centred care training was the exception rather
than assumed good practice, but it highlights the lack of
comparability of Usual Care between UK and non-UK
care homes. In addition, there are distinct funding
models of dementia care across countries and, therefore,
the economic evaluation data from these RCTs are not
directly applicable to a UK context. Therefore, a defini-
tive RCT of DCM™ in the UK, building on previous
work, is needed to inform the delivery of person-centred
dementia care within UK care homes. The additional
knowledge to be gained from this trial, beyond that
within research conducted to date, is that:
 It will reflect conditions of DCM™ implementation in
usual practice, being a pragmatic trial, compared to
the explanatory designs of previous trials; in particular
with care home staff rather than researcher led cycles
of DCM™ implementation. The study design, size
and statistical power will permit definitive
conclusions to be drawn regarding the efficacy of
DCM™ as an intervention in care home settings
 Three cycles of the DCM™ intervention will be
implemented and follow-up will be over a period of
16 months; considerably longer than in previous
trials where follow-up has been a maximum of 10
months. This is beneficial since some practice
changes, for example to underlying care culture, are
likely to require time to implement and, therefore, a
longer follow-up period is necessary to investigate
any such effects
 This trial will conduct a full economic evaluation
utilising a pragmatic trial design and, therefore,
will be able to offer a definitive position on
cost-effectiveness. Only one of the previous trials
conducted an economic evaluation and given its
explanatory design, these findings cannot be
confidently generalised
 The trial design builds on that of the three previous
explanatory trials, meaning its design is optimal for
assessing efficacy of DCM™ as an intervention in
care home settings
Aims and objectives
The aim of the trial is to evaluate the clinical and cost-
effectiveness of DCM™ in addition to Usual Care (UC)
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compared to UC alone for people with dementia living
in care homes in the UK.
Primary objective
To determine if DCM™ plus UC (i.e. the intervention) is
(1) more effective in reducing agitation as measured by
the total Cohen-Mansfield Agitation Inventory (CMAI)
score and (2) more cost-effective than UC alone (i.e. the
control), 16 months following randomisation of care
homes.
Secondary objectives
Secondary objectives are to investigate the effectiveness
of the intervention at 6 and 16 months post randomi-
sation in: (1) reducing BSC in residents over time as
measured by the CMAI and the NPI, (2) reducing the
use of antipsychotic and other psychotropic drugs, (3)
improving resident mood and quality of life, (4) impro-
ving staff well-being and role efficacy, and (5) improving
the quality of staff/resident interactions over time, as
measured by the Quality of Interactions Schedule
(QUIS). It will also explore (6) the safety profile of the
intervention as assessed by the number and types of
adverse events, (7) any differential predictors of the
effects of an intervention, and (8) the process, challenges,
benefits and impact of implementing the intervention.
Methods/design
Design
This trial has been designed to be a pragmatic, multi-
centre, cluster-randomised controlled trial of DCM™ plus
UC versus UC alone. There will be four types of trial
participants: care homes, residents, their relative/friend
and care home staff members. The trial will take place
in residential, nursing and dementia UK care homes
across West Yorkshire, Oxfordshire and London. From
these areas, 50 care homes will be recruited from a
random sample, within which 750 residents, their
relative/friend (where eligible) and all eligible, consented,
care home staff will be registered. Following participant
identification and consent, baseline assessments will be
undertaken and then the care homes will be randomised
in a ratio of 3:2 to receive intervention or control.
Outcome measures will be obtained at 6 and 16
months following randomisation. Additional to the primary
analysis, there will be an integral cost-effectiveness analysis
and a process evaluation. Figure 1 outlines the schedule for
all trial activities.
Inclusion and exclusion criteria
Care home criteria
A care home meeting all of the following criteria at
screening will be eligible for this trial:
 Has a sufficient number of permanent dementia
(based on a formal diagnosis or Functional
Assessment Staging of Alzheimer’s Disease (FAST)
[42] score of 4+) residents eligible to participate
in the study in order to achieve a minimum of 10
residents registered to take part
 Has a manager or nominated person agreeing to
sign up to the trial protocol as research lead for the
duration of the project?
 Agrees to release staff for DCM™ training and
subsequent mapping processes
 Is within the catchment area
A care home meeting any of the following criteria will
not be eligible for this trial:
 In the view of the research team, is not suitable
for inclusion due to being subject to Care Quality
Commission enforcement notices, admission bans
or relevant moderate or major Care Quality
Commission compliance breaches
 Is receiving other special support for specific quality
concerns, such as being currently subject to, or have
pending, any serious safeguarding investigations, or
receiving voluntary or compulsory admissions bans,
is in receipt of local commissioning special support
due to quality concerns
 Has used DCM™ as a practice development tool
within the 18 months prior to randomisation or is
planning to use DCM™ over the course of trial
involvement
 Is taking part, has recently taken part in, or is
planning to take part, in another trial that conflicts
with DCM™ or with the data collection during the
course of their involvement in the trial
Resident criteria
Residents meeting all of the following criteria at screening
will be eligible for this trial:
 Is a permanent resident within the care home –
defined as a person residing in the care home
and not present for receipt of respite or day-care
only
 Has a formal diagnosis of dementia or score 4+ on
FAST [42] as rated by the home manager or another
experienced member of staff
 Is appropriately consented (in accordance with the
Mental Capacity Act [43] and clinical trial guidance
on informed consent [44–46])
 Has an allocated member of staff willing to provide
proxy data
 Has sufficient proficiency in English to contribute to
the data collection required for the research
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Residents meeting any of the following criteria will not
be eligible for this trial:
 Is known by the care home manager and/or relevant
senior staff member to be terminally ill, e.g. formally
admitted to an end of life care pathway
 Is permanently bed-bound/cared for in bed
Staff criteria
1. Proxy informant: to be eligible to provide proxy data
staff must meet all of the following criteria:
 Be a permanent or contracted member of staff
 Know the resident well, as assessed by their key
worker status and/or the judgement of the home
manager
Staff are ineligible if they meet any of the following
criteria:
 Working in the home as agency or bank staff
 Have consented to be one of the home’s trained
DCM™ mappers
 Have acted as a nominated consultee for any
residents in the trial
2. Provision of staff measures: staff meeting all of the
following criteria will be eligible to provide data on
the staff measures:
 Is a permanent, contracted, agency or bank
member of staff at time of data collection
 Provides consent to providing data for the trial
through return of the Staff Measures booklet
 Has sufficient proficiency in English to contribute
to the data collection required for the research
Staff meeting the criterion below will not be
eligible to provide data on the staff measures for
this trial:
 Be acting as a nominated consultee for any
residents participating in the trial
3. Dementia Care Mapper: to be eligible to undertake
this role staff must:
 Be a permanent or contracted member of staff
 Have the right skills and qualities to be a mapper
as assessed by the home manager in accordance
with guidance provided by the research team, and
 Provide consent to becoming a mapper, to
implementing the DCM™ process as per the
research protocol and to participate fully in the
process evaluation
Staff who meet any of the following criteria are not
eligible to be a mapper:
 Work in the home as agency or bank staff
 Have acted as a nominated consultee for any
residents participating in the trial
 Provide proxy data for any residents participating
in the trial
Relative/friend criteria
To be eligible to provide proxy data about a resident,
relatives/friends must:
 Have visited the resident on a regular basis over the
past month (i.e. at least once per week)
 Be willing to provide data at a time convenient to
them
 Have sufficient proficiency in English to contribute
to the data collection required for the research
Eligibility waivers to inclusion and exclusion criteria
are not permitted.
Recruitment
Care home recruitment
Recruitment will begin with an initial eligibility scree-
ning (24 beds or larger in order to ensure that minimum
cluster size is likely to be achieved and providing care to
older people) of all care homes in the recruitment hub
areas (West Yorkshire, Oxfordshire, London) via publicly
available information, after which care homes will be
approached from those deemed eligible using two-stage
sampling. In the first stage, catchment areas within each
recruitment hub, defined by postcode prefix for West
Yorkshire, boroughs for London and geographical area
for Oxfordshire, will be selected in rotation. In the
second stage, all the care homes within catchment areas
will be randomly ordered and, at each rotation, a batch
of 12 care homes from the catchment area will be sent
invitation information by post. This method ensures
geographical closeness of care homes approached for
recruitment at the same time, which will support mul-
tiple short recruitment visits to be undertaken with
minimised travel. Sampling and care home approach will
be staggered across the recruitment period.
Researchers will contact homes invited to participate
by telephone after sending an initial postal invitation.
For interested care homes, the researcher will complete
initial eligibility screening via telephone and then visit
the care home to determine full eligibility and complete
the recruitment process. Once all the care homes within
a catchment area batch have been contacted and a
decision regarding participation made, the researcher
will move onto the next batch from the next catchment
area until sufficient homes have been recruited. In this
way, it is intended that the care home sample will be
representative of the entire region sampled, and that any
deviations from this will be known and can be adjusted
for. The target is for four homes to be recruited per
month across the whole trial.
Given that DCM™ is designed to be used alongside
training in person-centred dementia care, all care homes
will be audited using a training audit tool designed by
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the research team. This will ensure that each home in
the trial meets at least minimum dementia training
levels defined in terms of both content of the training
and proportion of staff trained (minimum 20 % of direct
care staff ). If the training audit finds that a home has
not provided staff with a minimum level of dementia
awareness training, staff will be provided with a half-day
dementia awareness course. Based on existing published
data [45], we expect up to 20 % of homes to require this
dementia awareness package.
Resident recruitment
Following the training audit, the researcher will meet
with the care home manager and/or relevant senior staff
member to identify all eligible residents to be approached
to take part in the trial. All residents will be reviewed for
eligibility by the researcher through discussions with the
manager, whilst maintaining anonymity. All eligible resi-
dents will then be approached to participate. It is expected
that approximately 15 residents will be recruited at each
participating care home. Reasons for ineligibility will be
recorded.
Staff recruitment
Care home staff can be recruited into four roles: (1) as
proxy informants, providing data about resident partici-
pants, (2) as a staff participant providing data about him
or herself, (3) as a mapper who will be responsible for
implementing the intervention, and (4) as a nominated
consultee (see informed consent). Role 4 is mutually
exclusive from all other roles, so any staff member
recruited as a nominated consultee will not be permitted
to undertake any other role within the trial. Roles 1 and
3 are also mutually exclusive, so staff recruited as
mappers will not be permitted to act as proxy infor-
mants. Recruitment to all staff roles will occur at
baseline and at subsequent time points where necessary
due to withdrawal. For role 2, recruitment will take place
at baseline and at each further data collection point, due
to the expected annual turnover rates of staff in each
care home.
Relative/friend recruitment
The resident (where possible), or the care home manager,
will be asked to identify a relative or close friend of the
resident, who visits at least once per week, to be
approached to provide proxy data for the trial. The
relative/friend will be contacted by post with information
about the trial and asked to return a signed consent form
to the care home if they agree to take part. The person
providing proxy data may differ from the residents’
personal consultee, where one is appointed (see informed
consent).
Intervention
Dementia Care Mapping (DCM™)
DCM™ will be implemented according the standard
procedures identified in the DCM™ 8 User’s Manual
[26]. The intervention comprises training two care
home staff in use of DCM™ followed by implemen-
tation of three full mapping cycles. Two eligible staff
members will be identified as mappers in all homes
prior to randomisation and will be consented at base-
line. After completion of the standard 4-day DCM™
training course, the mappers will run briefing sessions
1–2 weeks prior to undertaking the mapping observa-
tions. During the briefing session, mappers will con-
sult with staff about selection of appropriate residents to
be mapped. Residents chosen for inclusion in mapping
observations do not have to be trial participants and
verbal consent from residents to be observed will be
gained by the mappers ahead of mapping observations
commencing. Mapping involves the mappers continuously
observing between two and five people with dementia,
over a period of four to six consecutive hours, in com-
munal living areas only. The mappers will then analyse
the data they collect and present it in a report that will be
fed back to the staff team. During the feedback session, an
action plan will be produced in collaboration with the staff
team, which will detail areas that the home aims to
improve, based on the DCM™ data. Progress on these
actions is monitored during the next mapping cycle. The
first cycle should be completed by approximately 3
months post randomisation and the second and third
cycles at approximately 8 months and 13 months post
randomisation, respectively. An expert mapper, who is a
practitioner experienced in the implementation of DCM™,
will provide support to each care home during completion
of their first cycle of mapping in order to maximise inter-
vention fidelity across all homes. Telephone/email support
for DCM™ implementation will be available to all care
homes thereafter through the DCM™ lead for the trial,
if required. Mappers will be asked to complete and
return data on mapping practice for all three mapping
cycles including: information on numbers of staff in
the care home receiving DCM™ briefing; number of
hours of mapping; number of residents mapped; num-
ber of staff attending feedback sessions and number
of action plans developed. Mappers will be provided
with a standard reporting template to gather this
information.
Usual Care
UC is defined as normal care delivered within the
setting (as measured by training audit, a bespoke UC
Questionnaire and the Care Home Context and
Organisational Questionnaire). No restrictions will be
imposed on current practices or on homes undertaking
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additional development or training as part of UC, with the
exception of control arm homes being required not to
implement DCM™ during their trial involvement period.
Person-centred care is considered best practice within
dementia care [13] and as such care homes are expected
to provide staff with appropriate training to deliver care of
this type [47].
Registration and randomisation
Residents will be registered centrally with the Clinical
Trials Research Unit (CTRU) at the University of Leeds
after care home recruitment, the care home training
audit, confirmation of eligibility, informed consent and
collection of resident baseline data.
Once all residents within a care home have been
registered, care homes will be randomised centrally at
the CTRU to receive DCM™ + UC or UC, leading to two
sources of clustering: cluster-randomisation and DCM™
treatment provision. The former occurs at randomi-
sation (care homes are nested within treatment arms),
the latter afterwards (care homes are partially nested
within arms) so we anticipated that the clustering effect
will vary across arms, and assumed a higher design effect
in the intervention arm. Care homes will be randomised
on a 3:2 basis. A computer-generated minimisation
programme incorporating a random element will be
used to ensure treatment arms are balanced for the
following care home characteristics: (1) home/unit type
(general residential/nursing, specialise in dementia care),
(2) size (large at least 40, medium/small fewer than 40),
and (3) provision of dementia awareness training by
research team (yes, no), (4) recruitment hub (West
Yorkshire, Oxfordshire, London). The latter was chan-
ged from prior use of DCM™ in the last 5 years as
balancing the intervention across recruitment hubs
was considered more important. Following randomisa-
tion, a member of the research team will inform the
care home manager of their allocation and for those
homes allocated to DCM™ + UC, the staff consented
to take on the role of mappers will also be informed,
so arrangements for attendance at DCM™ training can
be made.
Data assessments
Assessments will be undertaken at screening (prior to
consent); baseline (prior to resident registration); 6
months post randomisation and 16 months post
randomisation. Baseline data collection visits will be
conducted over approximately 3 weeks in each home
and follow-up visits over a 1–2-week period. Required
data, assessment tools, collection time points and
processes are summarised in Table 1.
Outcomes
The primary outcome is agitation at 16 months follo-
wing randomisation. The primary measure of agitation is
the Cohen-Mansfield Agitation Inventory (CMAI) [48]
rated by a staff member who knows the resident well.
The Pittsburgh Agitation Scale (PAS) [49] and an
adapted CMAI (see below), rated by an independent
researcher not involved in any other data collection
within that care home and blinded to allocation, will
provide concurrent validity. This addresses the issue of
potential bias of staff responses, based on the inability to
blind them to allocation status.
There are a number of secondary outcomes each rela-
ting to residents, staff or care homes. Secondary out-
comes at 6 and 16 months post randomisation relating
to residents are: Neuropsychiatric Inventory (NPI) [50];
DEMQOL-Proxy, Quality of Life in Late Stage Dementia
(QUALID) [51]; QOL-AD [52], EuroQol five dimen-
sions, five levels (EQ-5D-5 L) [53]; the prescription and
use of psychotropics, memantine, benzodiazepines and
anti-depressants; and, safety reporting (serious adverse
events (SAEs)). Secondary endpoints at 6 and 16 months
post randomisation relating to staff are: General Health
Questionnaire (GHQ-12) [54] and Sense of Competence
in Dementia care Staff (SCIDS) scale [55]. Secondary
endpoints relating to homes are: intervention fidelity (at
16 months) and Quality of Interactions Schedule (QUIS)
[56] at 6 and 16 months.
Outcome measures
Resident-related outcome measures
Agitation Cohen-Mansfield Agitation Inventory
(CMAI) [6, 48]:
The CMAI measures 29 agitated or aggressive beha-
viours [57] on frequency, using a seven-point scale (1–7)
ranging from ‘never’ to ‘several times an hour’ based on
behaviours over the previous 2 weeks. A total score is
obtained by summing the 29 individual frequency scores
(range 29–203). It has good psychometric properties
[58] including construct validity and factor structure
[59], concurrent validity [60] reliability [61] and test-retest
reliability [62] in care home settings. There are also
available data on expected change in points from previous
similar studies supporting the sample size calculation. The
CMAI will be completed in accordance with the CMAI
Manual [48] via staff proxy report in the context of an
interview with a trained researcher.
Pittsburgh Agitation Scale [49]:
The PAS is an observational rating of the presence
and intensity of agitation within four behaviour groups,
which has good reported reliability and validity [49].
Observations are conducted for between 1 and 8 h. In
this trial, data collection will be undertaken by an inde-
pendent researcher using a standardised observation
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Table 1 Summary of assessments
Assessment Type Method of completion Timeline
Screening Baseline 6 months 16 months
Care home eligibility CRF Researcher assessment X
Training review CRF Researcher assessment X
Dementia awareness training CRF Dementia awareness trainer X
Resident screening (demographics) CRF Researcher assessment X
Staff mapper screening CRF Researcher assessment X
Consent (staff mapper, resident (includes
personal/nominated consultee), staff
proxy informant, RF proxy informant)
Consent Form Self-completion (witnessed) X X
Participant eligibility (staff mapper, resident,
staff proxy informant, RF proxy informant)
CRF Researcher assessment X X
Participant contact details (resident, staff
proxy informant, RF proxy informant)
CRF Researcher assessment X X
Cohen-Mansfield Agitation Index
(CMAI) abridged
Questionnaire booklet Independent researcher
observations (R)
X X X
Pittsburgh Agitation Scale (PAS) Questionnaire booklet Independent researcher
observations (R)
X X X
Care home manager demographics Questionnaire booklet Researcher interview (CM) X X X
Care home demographics Questionnaire booklet Researcher interview (CM) X X X
Group Living Home Characteristics (GLHC) Questionnaire booklet Researcher assessment (CH) X X X
Environmental Audit Tool (EAT) Questionnaire booklet Researcher observations (CH) X X X
Quality of Interactions Schedule (QUIS) Questionnaire booklet Researcher observations (R/S) X X X
Staff proxy informant demographics Questionnaire booklet Researcher interview (SP) X X X
Resident demographics Questionnaire booklet Researcher assessment X X X
RF proxy informant demographics Questionnaire booklet Researcher interview (RF) X X X
Cohen-Mansfield Agitation Index (CMAI) Questionnaire booklet Researcher interview (SP) X X X
Neuropsychiatric Inventory (NPI-NH) Questionnaire booklet Researcher interview (SP) X X X
Functional Assessment Staging (FAST) Questionnaire booklet Researcher interview (SP) X X X
Clinical Dementia Rating (CDR) Questionnaire booklet Researcher interview (SP) X X X
DEMQOL-Proxy Questionnaire booklet Researcher interview (SP/RF) X X Xa
EQ-5D-5 L Questionnaire booklet Researcher interview (SP/RF/R) X X Xa
QUALID Questionnaire booklet Researcher interview (SP/RF) X X Xa
QOL-AD Questionnaire booklet Researcher interview (R) X X X
Resident comorbidities Questionnaire booklet Researcher assessment X X X
Health care resource use Questionnaire booklet Researcher assessment X X X
Prescription medications CRF Researcher assessment X X X
Resident registration Questionnaire booklet Researcher assessment X X
Staff booklet Questionnaire booklet Self-completed (S) X X X
General Health Questionnaire (GHQ-12) Questionnaire booklet Self-completed (S) X X
Sense of Competence in Dementia
care Staff (SCIDS) scale
Questionnaire booklet Self-completed (S) X X X
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period (between 10.00 and 17.00 hours), on consented
residents within communal areas.
Adapted CMAI [48]:
The adapted CMAI is a researcher-completed, direct
observational tool, which records observed levels of
agitation over a single observation period, on a single day.
It was adapted specifically for the purpose of this trial
since the original CMAI scale considers proxy reported
behaviours over the previous 2 weeks and is not suitable
for direct observational use on a single day. Adaption in-
cluded changing the CMAI’s seven-point scale related to
the previous 2 weeks to a four-point scale (‘never’ to ‘sev-
eral times an hour’) appropriate for observations on a sin-
gle day. In this trial, data collection will be standardised to
observations of consented residents within communal
areas between 10.00 and 17.00 hours.
Behaviours that staff may find challenging to
support Neuropsychiatric Inventory-Nursing
Home (NPI-NH) [50]:
The NPI-NH is a validated 12-item measure with
good reported reliability, that records a range of BSC
including, delusions, hallucinations, agitation/aggression,
depression/dysphoria, anxiety, elation/euphoria, apathy/
indifference, disinhibition, irritability/lability, aberrant
motor behaviour, sleep and night-time behaviour disor-
ders and appetite/eating disorders [50]. It will be com-
pleted via staff proxy report in the context of an interview
with a trained researcher.
Quality of life
Multiple quality of life measures have been imple-
mented since no one measure was identified that could
provide the required sensitivity to quality of life in this
participant group, and which could facilitate participant
self-report in those with severe dementia.
DEMQOL-Proxy [63]:
The DEMQOL-Proxy is a quality of life measure with
32 items covering mood, behavioural symptoms,
cognition and memory, physical and social functioning
and general health that are administered by an inter-
viewer. It is completed by a carer of the person with
dementia and administered by an interviewer. It has
acceptable psychometric properties for measuring
quality of life in dementia [64] and has been valued
to enable the derivation of preference based indices
(utility values) [65] and will thus be employed in the
secondary cost-utility analyses. It will be completed
via staff proxy report in the context of an interview with
a trained researcher. The relative/friend proxy will also
complete the DEMQOL-Proxy where available to provide
complimentary additional data.
EQ-5D-5 L/EQ-5D-5 L Proxy [53]:
EQ-5D is a standardised measure of health outcome that
provides a single index value for health status [66, 67]. It
has five items covering: usual activities, self-care, mobility,
pain and anxiety/depression, each with five response op-
tions (no problems, slight problems, moderate problems,
severe problems and unable to do task). It will be com-
pleted via staff proxy report in the context of an interview
with a trained researcher. The resident will complete the
EQ-5D-5 L when able via interview with the researcher
and the relative/friend proxy, where recruited, will
complete the EQ-5D-5 L Proxy to provide complimentary
additional data.
Quality of Life in Late Stage Dementia
(QUALID) [51]:
The QUALID is an 11-item proxy completed scale that
rates the presence and frequency of quality of life-
related behaviours over the previous 7 days. It is reliable
and valid for rating quality of life in people with moder-
ate to severe dementia and has good internal
consistency, test-retest reliability and inter-rater reliabil-
ity. It will be completed via staff proxy report in the con-
text of an interview with a trained researcher. The
relative/friend proxy will also complete the QUALID
where available to provide complimentary additional data.
Table 1 Summary of assessments (Continued)
Safety reporting CRF Researcher assessment Monthly following
randomisation
RUSAE Report CRF Researcher assessment As highlighted.
Mapper
training
Cycle 1 Cycle 2 Cycle 3
Mapper training CRF DCM™ trainer X
DCM™ adherence Questionnaire booklet/CRF DCM™ expert/ independent
reviewer
X X X
DCM™ briefing summary CRF CH mapper X X X
DCM™ feedback summary CRF CH mapper X X X
Key: CRF Case Report Form, CH care home observations, CM care home manager, DEMQOL-Proxy Dementia Quality of Life measure – proxy version, EQ-5D-5 L
EuroQol five dimensions, five levels, QUALID Quality of Life in Late-Stage Dementia, QOL-AD Quality of Life in Alzheimer’s disease measure, R resident, RF relative/
friend proxy informant, RUSAE Related Unexpected Serious Adverse Event, S staff, SP staff proxy informant, Xa – only for relative/friend informants consented at
baseline and still meeting eligibility criteria
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QOL-AD [68]:
The QOL-AD is a 13-item self-report questionnaire. It
has good reported internal reliability, test-retest relia-
bility and convergent validity [68]. It is reported to be
reliable for use with people with mild to moderate
dementia (11 or greater on the MMSE [69] and more
severe dementia (MMSE of >2)) [70, 71]. It will be
completed by the resident in the context of an interview
with a trained researcher.
Use of health care services Health care resource use
measure:
This measure is adapted from one that has recently
been piloted in a care home feasibility trial [72]. It cap-
tures primary (e.g. general practitioner and nurse visits)
and secondary (Accident and Emergency Department
and other hospital visits) health care usage. This will be
completed by the researcher from care home records.
Dementia severity Clinical Dementia Rating Scale
(CDR) [73]:
The CDR is a standardised scale for rating the severity
of dementia from no cognitive impairment to severe or
advanced dementia [74] and is completed by a trained
assessor via informal interview/conversation with the
person or a proxy. It will be completed by the researcher
in discussion with the staff proxy.
Functional Assessment Staging in Alzheimer’s Dis-
ease (FAST) [42]:
The FAST is a scale designed to capture the functional
severity of dementia. It is particularly designed for use in
more moderate to severe dementia. It is completed by
proxy report from a caregiver. This will be completed by
the researcher with information from a staff informant.
Staff-related outcome measures
Staff measures are distributed by the researcher or care
home manager and returned in a sealed envelope either
directly to the researcher or posted into a secure locked
box located within the care home during data collection
visits. Alternatively, staff may return the measures direct
to the CTRU using a pre-paid envelope.
Work stress General Health Questionnaire 12-item
(GHQ-12) [54]:
The GHQ-12 is a measure of stress/psychological well-
being and is used with the general population. It has
good reported psychometric properties [75].
Job or role efficacy Sense of Competence in
Dementia care Staff (SCIDS) scale [55]:
The SCIDS is a self-complete 17-item scale that
measures staffs’ sense of their own competence with
regard to delivery of dementia care across four sub-
scales (professionalism, building relationships, care
challenges, sustaining personhood). It has acceptable
internal consistency and test-retest reliability [55].
Care home-related outcome measures
Care quality Quality of Interactions Schedule
(QUIS) [56]:
The QUIS is an observational measure of the quality of
interactions between staff and people with dementia,
which has reported adequate inter-rater reliability and
sensitivity [76]. The QUIS is administered via researcher
observations, using a time-sampling approach [56, 77].
Data are amalgamated to provide a rating of the quality
and quantity of interactions at the care home. In this
trial, observations will be undertaken by a researcher for
15-minute periods, in communal areas in the care home,
during two 2-h observations (one a.m. and one p.m.)
during a 7-day period.
Care home environment, context and organisation
Environmental Audit Tool (EAT) [78]:
The EAT is a valid and reliable instrument that can be
used to differentiate between the quality of environ-
mental design in various types of dementia care facilities
[78]. It is completed by the researcher through obser-
vation and with information from a senior staff member.
Care home context and organisational questionnaire
Information about the care home context and orga-
nisation will be gathered using a specially designed ques-
tionnaire asking questions about the home (size, type,
ownership, geography, staff turnover, staff ratios, resident
demographics, etc.), manager (qualifications, length of
time in post, leadership style, etc.) and staff (qualifica-
tions, length of time in post, English as first language,
etc.) demographics. It is completed by the researcher with
information from a senior staff member.
Group Living Home Characteristics Questionnaire
(GLHC) [79]:
This is a measure of the style of care being delivered
in the home. It examines how ‘home-like’ the care
delivered is. It is completed by the researcher with in-
formation from a senior staff member.
Bias and blinding
Due to the nature of the intervention, it will not be
possible to blind care homes or staff to the allocation
status. To minimise the potential for bias, the trained
mappers will not be involved in providing any out-
come data. To ensure consistency, where possible the
same staff member will be asked to complete resident
measures at each data collection point. All data will
be gathered by trained researchers in discussion with
the informant with the exception of the staff mea-
sures questionnaires, which will be completed
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independently by staff. To ensure reliability and to
restrict the potential for researcher bias, intra-rater
reliability will be achieved for all researchers at train-
ing. Effort will be made to blind all trial researchers
to allocation status. The researcher conducting the
observations for the PAS and abridged CMAI will be
independent and will remain blind. Any unblinding
will be recorded and unblinded researchers will not
conduct any further follow-up data collection in those
care homes.
Sample size
The sample size calculations were based on assumptions
of an average of 40 residents in each care home, and that
at least 60 % of these would meet the eligibility criteria
and 65 % of those eligible would be willing to provide
informed consent (i.e. 15 residents recruited from each
care home). Calculations were based on a normally
distributed outcome: the mean difference in CMAI scores
between arms at 16 months. Fifty care homes, each
recruiting 15 residents, will result in 750 residents overall
and provide 90 % power to detect a clinically important
difference of 3 CMAI points (standard deviation (SD) 7.5
points) with a two-sided 5 % significance level. This allows
for 25 % loss to follow-up (cluster size of 11 residents
available for analysis) based on Chenoweth et al. [14]
leading to an inflation factor of 2.0 (intracluster corre-
lation coefficient (ICC) no greater than 0.1). The ass-
umption that the ICC will be no larger than 0.1 was based
on an ICC for CMAI reported by Fossey et al. [27]
when evaluating effectiveness of a psychosocial inter-
vention on antipsychotic use in nursing home residents
with dementia.
Methodological improvements building on previous
studies
Through correspondence with the authors of all three
previous trials on the efficacy of DCM™, we were able to
identify key study design strengths, challenges and diffi-
culties encountered. Key methodological developments
in the EPIC trial include:
 Adoption of a pragmatic trial design. This enables
generalisation of the treatment effects to practice in
the UK and important data to be collected on
cost-effectiveness
 Use of an independent researcher assessment of the
primary outcome at each time point, permitting
assessment of any bias that may be caused by being
unable to blind study participants to intervention
allocation
 Collection of quality of life data from three sources
where available – staff-proxy, self-report and relative
proxy
 Collection of quality of life data using three measures,
permitting, use of measures we believe to be most
sensitive for use in this population (QUALID),
quality-adjusted life years (QALYs) to be calculated
(DEMQOL-Proxy) and self-report in as many
residents as possible (QOL-AD)
 Randomisation of sites at a care home rather than
unit level so there is a significantly reduced chance
of control contamination in care home sites where
one or more units may be participating but may be
randomised to the intervention separately
 Inclusion of a process evaluation including in-depth
intervention fidelity assessment and qualitative
examination of implementation issues
Statistical analysis
A single final analysis is planned when all follow-up data
have been collected and the primary analyses will be
carried out on an intention-to-treat basis, utilising all
available follow-up data, comparing treatments as allocated.
It is expected that a sizeable proportion of residents
will be missing from the main analyses, and that missing
data can be predicted by known variables, hence the
principal method for handling missing scale data will be
multiple imputation under the Missing at Random
(MAR) assumption. Sensitivity analyses will be carried
out to assess the impact of the choice of imputation
model and of assuming data are Missing Not at Random
(MNAR) as appropriate.
The impact of cluster randomisation is expected to be
equal across arms but that of treatment provision is not.
As such, the principal method for handling clustering
effects will be to fit a multilevel model that allows care
home- and resident-level variances to differ across arms.
A sensitivity analysis will be conducted fitting a random
intercept model assuming equal total variances. The
resident-level primary outcome of agitation (continuous
CMAI score) will be analysed at 16 months post
randomisation using a linear two-level heteroscedastic
regression model [70], adjusting for design factors, with
a contrast for intervention and control. The model will
be adjusted for the following fixed effects: care home
(level 2) covariates (home type and size, provision of
dementia awareness training and hub) and resident
(level 1) covariates (severity of dementia, age and
baseline CMAI score). Unadjusted and adjusted ICCs,
treatment effect estimates and corresponding 95 % con-
fidence intervals will be presented.
For residents where a PAS and an abridged CMAI
score are also available, a sensitivity analysis will be
conducted replacing the CMAI score in the primary
analysis with the PAS and abridged CMAI scores
looking for consistency in the size and direction of
effect.
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Secondary outcome measures will be analysed using a
similar modelling strategy as described for the primary
analysis. Where outcomes are continuous, linear models
will be fitted; where binary, logistic models will be fitted.
Change in primary and secondary outcomes over time
(6 and 16 months) will be analysed with three-level
multilevel models with contrasts for treatment, time and
the treatment-by-time interaction, in which outcomes
are nested within residents and care homes. A similar
correlation structure will be assumed for care homes
and residents, but correlation over time will also be
considered at the outcome level.
A number of exploratory subgroup analyses are
planned which will be specified in detail in the Statistical
Analysis Plan. These will include care home- and
resident-level factors such as type of care home, severity
of dementia and NPI subgroup clusters.
Health economic evaluation
The proposed primary endpoint and methods for the
economic evaluation follow the reference case set out
by the National Institute for Health and Care Excel-
lence (NICE) [80]. The primary economic analysis will
be a cost-utility analysis over 16 months presenting
incremental cost-effectiveness ratios (ICER) for interven-
tion (UC +DCM™) versus control (UC), with effects
expressed in terms of quality-adjusted life years (QALY).
The analysis will adopt the health care and personal social
services perspective. Analysis of the uncertainty surroun-
ding the ICER will be undertaken using non-parametric
bootstrap simulation (10,000 simulations) and presented
on a cost-effectiveness plane and a Cost-Effectiveness
Acceptability Curve (CEAC) [81]. A net benefit regression
approach will also be employed using the model selected
for the clinical effectiveness analysis [82]. Where Net
Monetary Benefit (NMB) = (£20,000 ×QALYs) −Costs
NMB regression will enable covariate control and
clustered analysis. There will be no modelling forward
of benefits and discounting (at 3.5 %) will be con-
ducted for values post 12 months. We will use the
NICE willingness to pay per incremental QALY
threshold range (lambda [λ] = £20,000-£30,000) to de-
termine cost-effectiveness.
Effects
Utility values will be captured using the EQ-5D-5 L
(primary) and DEMQOL-Proxy-U [83] (secondary).
Residents will self-report where able on the EQ-5D-5
L or the EQ-5D-Proxy will be used. Resident- and
proxy-reported data will be reported and analysed
separately. However, given that only a proportion of
residents will be able to complete the questionnaires,
we will explore whether it is valid to use one source
of data as a substitute for the other.
Costs
The total cost of DCM™ will incorporate the costs of
training staff and staff time spent delivering the inter-
vention as well as travel costs and any other expenditure
(e.g. on training materials). The assumption for the
analysis will be that the local authority pays for the
provision of care home care for residents. We will
include a sensitivity analysis where a proportion of
residents are considered to pay toward their care home
costs. Researchers will collect health care resource use
data for each resident participating in the trial at
baseline, 6 and 16 months using individual care home
records and care plans. This will be supplemented by
care home-level data collection, which will enable some
validation of individual-level data. Unit costs for health
service staff and resources will be obtained from national
sources such as the Personal Social Services Research
Unit, the British National Formulary and NHS reference
cost database.
Trial governance
The Trial Management Group, comprising the chief
investigator, CTRU team, co-investigators and researchers
will be assigned responsibility for the clinical set-up, on-
going management, promotion of the trial, and for the
interpretation of results. An independent Data Monitoring
and Ethics Committee will be established to review the
safety and ethics of the trial. An independent Trial Stee-
ring Committee will be established to provide overall
supervision of the trial, including trial progress, adherence
to protocol, resident safety, and consideration of new
information. The trial sponsor will ensure responsibility
and accountability for trial conduct and procedures asso-
ciated with the protocol. Individual care homes remain
responsible for participant care as usual. Trial researchers
will have the opportunity to highlight any safeguarding
issues of concern with the Trial Steering Committee and
to individual care homes, in line with relevant guidance
from the local authority, care home, and the trial team.
Public and Patient Involvement
Service users and carers will play an integral role
throughout this programme of research to ensure that
the work is based on the principles of Patient and Public
Involvement (PPI). PPI will be fulfilled in partnership
with the Alzheimer’s Society via involvement of mem-
bers of their Research Network, and via inclusion of PPI
representatives (relatives and persons with Dementia) on
the Trial Management Group and Trial Steering Com-
mittee. Specifically, PPI representatives will be involved
in the review of participant information and general as-
pects of trial design and be involved in all decisions
made by the Trial Management Group. The intention is
to involve service users in the interpretation of results
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and appropriate dissemination of information at the end
of the trial.
Discussion
Pilot phase
A pilot was built into the trial to pilot trial procedures
to inform modification to, and streamlining of, research
processes for the remaining care homes. Two care
homes (one in West Yorkshire, one in London), were
recruited to the pilot 2 months ahead of start of the
planned recruitment phase. Three review periods
followed: the first focussed on care home screening and
recruitment processes, the second assessed trial burden to
participants, and the third adherence to determine if data
collection needed to be adapted or reduced. The trial
procedures described above were followed, and expe-
riences reviewed by the trial team. The changes made are
summarised below. Pilot homes will be included in the
final analysis.
Screening and recruitment review
One change made as a result of this review was impro-
vement to the Case Report Forms (CRFs). Changes to
the content and structure of some CRFs and creation
of new forms ensured that all CRFs reflected actual
processes and procedures that the researchers needed
to follow to accurately complete the complex screening
and recruitment process. A second change was made to
care home eligibility criteria. Originally, the criteria
stated that to be eligible a care home should have a
minimum of 24 permanent residents of whom at least
60 % were estimated to have dementia. However, this
did not always ensure that recruited care homes would
be able to provide an adequate number of trial partici-
pants. For example, large residential homes where the
general resident population did not include many
people with dementia, but contained a smaller special-
ist dementia unit failed to reach the threshold of 60 %
of residents with dementia within the care home overall
but could still achieve a viable cluster size of residents
with dementia within the specialist unit. Likewise, in
smaller homes, an adequate cluster of eligible residents
was not always available when both the 24 permanent
residents and the ‘60 % of residents with dementia’ cri-
teria were met, due to eligibility exclusions based on
other, resident-level, criteria. This was particularly the
case for nursing homes where residents had a range of
significant additional physical health problems. On the
other hand, the criteria also led to the exclusion of
some smaller dementia-specialist care homes that would
Table 2 Summary of burden assessment
Questionnaire Completed by Number of data points Mean time taken (min) Modal time taken (min) Range (min)
CMAI Staff proxy 24 07 10 (02–15)
NPI-NH Staff proxy 16 15 20 (08–24)
FAST Staff proxy 24 04 03 (02–14)
CDR Staff proxy 23 06 05 (03–12)
DEMQOL Staff proxy 24 09 05 (04–17)
EQ-5D Staff proxy 24 03 03 (02–07)
QUALID Staff proxy 24 07 07 (04–20)
Total Staff proxy 53 67 (34–74)
EQ-5D Resident 21 06 05 (02–28)
QOL-AD Resident 22 13 10 (05–20)
Total Resident 18 15 (12–30)
Visit details Relative/friend 8 02 01 (01–06)
DEMQOL Relative/friend 9 10 10 (01–30)
EQ-5D Relative/friend 9 04 05 (01–12)
QUALID Relative/friend 9 08 05 (01–20)
Total Relative/friend 26 22 (04–68)
Current comorbidities Researcher 24 05 02 (02–15)
Resource Use Form Researcher 22 10 10 (05–20)
Total Researcher 15 15 (07–30)
CDR Clinical Dementia Rating Scale, CMAI Clinical Dementia Rating Scale, DEMQOL Dementia Quality of Life measure, EQ-5D EuroQol five dimensions, FAST
Functional Assessment Staging of Alzheimer’ Disease, NPI-NH Neuropsychiatric Inventory-Nursing Home, QUALID Quality of Life in Late-Stage Dementia, QOL-AD
Quality of Life in Alzheimer’s disease measure
Surr et al. Trials  (2016) 17:300 Page 13 of 17
have been able to provide an adequate cluster size despite
having less than 24 permanent residents in total. As a
result, care home eligibility criteria were replaced with the
following:
• Has a sufficient number of permanent residents with
dementia (based on a formal diagnosis or Functional
Assessment Staging of Alzheimer’s Disease (FAST) score
of 4+) eligible to participate in the study in order to
achieve a minimum of 10 residents registered to take
part prior to care home randomisation
Burden review
The burden review was undertaken shortly after the
return of the baseline measures. Researchers and rela-
tives/friends were asked to provide details of the time
taken to collect each of the measures. A review of the
mean, mode and range of time taken to complete each
questionnaire was completed (see Table 2). The number
of returned relative/friend measures was low and the
data on time taken to completion was varied and incon-
sistent. Therefore, it was not possible to reach a mea-
ningful conclusion regarding the data collection burden
on relatives/friends based on the pilot review alone.
The burden placed on staff completing proxy mea-
sures was of initial concern, given the upper completion
time of 74 minutes. However, the researchers advised
that proxy measures could be completed with a staff
member in multiple sessions of 15–20 min over one or
more days and longer completion times were often asso-
ciated with staff choosing to provide detailed responses
to measure items. Therefore, given the necessity of each
of the individual measures within the trial, it was not
possible to identify a suitable way to reduce this burden
in any meaningful way.
Adherence
Only two residents of a possible 26 (7.7 %) did not
complete self-report measures; one declined to answer
any of the item questions at all and one stopped half way
through the administration of the first questionnaire. It
was judged that the burden on the residents was not
overly demanding and that the measures used were likely
to be completed by a majority of trial participants. There-
fore, no changes were made to the number of measures
administered with residents. The researchers identified
two questions in the QOL-AD that appeared to be causing
anxiety/distress to some residents and were leading to
Allocation
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Enrolment:
CH Eligibility Screening X
CH Invitation to Participate X
CH Informed Consent X
Training Review X
Dementia Awareness Training • •
Resident Screening X
Participant Eligibility (Resident/Proxy Informant/Staff/Mapper) X X X
Participant Recruitment (Resident/Proxy Informant/Staff/Mapper) X
Resident Registration X
CH Randomisation X
Interventions:
Usual Care • •
Dementia Care Mapping X X X
Assessments:
CMAI (Cohen Mansfield Agitation Index) X X X
PAS (Pittsburgh Agitation Scale) X X X
Care Home Manager Demographics X X X
Care Home Demographics X X X
GLHC (Group Living Home Characteristics) X X X
EAT (Environmental Audit Tool) X X X
QUIS (Quality of Interactions Schedule) X X X
Staff Proxy Informant Demographics X X X
Resident Mental Capacity Check X X X
Resident Demographics X X X
RF Proxy Informant Demographics X X X
NPI-NH (Neuropsychiatric Inventory) X X X
FAST (Functional Assessment Staging) X X X
CDR (Clinical Dementia Rating) X X X
DEMQOL Proxy X X X
EQ 5D 5L X X X
QUALID X X X
QOL-AD X X X
Resident Comorbidities X X X
Healthcare Resource Use X X X
Prescription Medications X X X
Staff Demographics X X X
SCIDS (Sence of Competence in Dementia care Staff) X X X
Safety Reporting (Hospitalisations) • •
Qualitative Interviews (Process Evaluation) X
* If required - based upon Training Review
Post Allocation
Study Period
TIMEPOINT
CH 
Screening
Enrolment Training
Participant 
Recruitment
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist
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missing data on these items. The items related to a ques-
tion about satisfaction with management of their own
finances (which the resident may no longer be in control
of) and relationship with the residents spouse (who may
no longer be alive). Thus, a modified version of the QOL-
AD [84] specifically designed for use with people with
dementia in care homes was identified and implemented.
It excludes the two questions causing distress and includes
four additional questions on relationships with staff, ability
to live with others, taking care of yourself and the ability
to make choices in your life.
Other changes to the protocol implemented following
the pilot include a modification to the randomisation
stratification criteria which originally included ‘use of
DCM™ in the home over the last 18 months to 5 years’
and replacing it with ‘recruitment hub’ to ensure spread of
intervention homes across the three hubs, removing a
possible regional effect. The staff measures collection
process has been adapted to include the option for staff to
post their questionnaires directly back to the CTRU, as
some staff stated they felt uncomfortable leaving their
replies in the care home where other members of staff
might have access to them. Lastly, an additional process of
reminding intervention homes of an upcoming mapping
cycle by text message was implemented, in addition to
sending of newsletters and intervention paperwork via the
post, to increase potential intervention implementation.
To conclude, the pilot proved valuable for the researchers
to implement proposed trial processes and documentation
and to suggest adaptations, which have been implemented
in a timely manner. This has been important in ensuring
smooth running of the trial once recruitment rates have
increased.
Trial status
This is the protocol of a current trial; recruitment of
participants is on-going.
Additional notes
A Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) checklist is included for this
protocol (see Fig. 1).
Trial sponsor
Leeds Beckett University
University Research Office
James Graham Building
Headingley Campus
Leeds Beckett University
Leeds
LS6 3QS
Additional file
Additional file 1: Schedule of enrolment, interventions and
assessments. (PDF 122 kb)
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Random; MNAR, Missing Not at Random; NICE, National Institute for Health
and Care Excellence; NMB, Net Monetary Benefit; NPI, Neuropsychiatric
Inventory; PAS, Pittsburgh Agitation Scale; PPI, Patient and Public
Involvement; QALY, quality-adjusted life year; QOL-AD, Quality of Life in
Alzheimer’s disease measure; QUALID, Quality of Life in Late-Stage Dementia;
QUIS, Quality of Interactions Schedule; RCT, randomised controlled trial; SAE,
serious adverse event; SCIDS, Sense of Competence in Dementia Care Staff
scale; UC, Usual Care
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will make a further assessment of capacity to give informed consent. If a
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at the outset of the study, a further capacity assessment will be conducted
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